Maplight Therapeutics (NASDAQ:MPLT) Releases Quarterly Earnings Results

Maplight Therapeutics (NASDAQ:MPLT) posted its quarterly earnings data on Thursday. The company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.40) by $0.08, FiscalAI reports.

Maplight Therapeutics Stock Up 0.3%

MPLT traded up $0.03 during midday trading on Friday, reaching $11.61. 209,440 shares of the company’s stock were exchanged, compared to its average volume of 453,951. Maplight Therapeutics has a one year low of $9.10 and a one year high of $40.43. The firm has a market capitalization of $494.84 million and a price-to-earnings ratio of -0.28. The business has a 50-day simple moving average of $27.64 and a two-hundred day simple moving average of $24.58.

Analyst Ratings Changes

A number of research firms have weighed in on MPLT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maplight Therapeutics in a research note on Monday, July 13th. Lifesci Capital raised Maplight Therapeutics to a “strong-buy” rating in a research report on Thursday, May 14th. Craig Hallum reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Maplight Therapeutics in a research report on Tuesday, July 28th. Raymond James Financial set a $31.00 target price on shares of Maplight Therapeutics in a research report on Friday. Finally, Needham & Company LLC raised their price objective on shares of Maplight Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Four investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.67.

Insider Buying and Selling

In other Maplight Therapeutics news, Director Troy Cox acquired 15,620 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were acquired at an average cost of $9.52 per share, for a total transaction of $148,702.40. Following the completion of the acquisition, the director directly owned 15,620 shares of the company’s stock, valued at approximately $148,702.40. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James Woodruff Lillie sold 22,082 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $12.54, for a total transaction of $276,908.28. Following the completion of the transaction, the insider directly owned 202,380 shares of the company’s stock, valued at $2,537,845.20. This trade represents a 9.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Maplight Therapeutics

Several large investors have recently modified their holdings of the stock. Fcpm Iii Services B.V. bought a new stake in Maplight Therapeutics in the 4th quarter valued at $56,672,000. T. Rowe Price Investment Management Inc. acquired a new position in Maplight Therapeutics in the 4th quarter valued at $49,154,000. Goldman Sachs Group Inc. acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth $34,026,000. BlackRock Inc. acquired a new position in Maplight Therapeutics in the second quarter valued at about $36,741,000. Finally, Nan Fung Group Holdings Ltd acquired a new stake in Maplight Therapeutics during the fourth quarter worth about $17,060,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.